Healios KK
TSE:4593

Watchlist Manager
Healios KK Logo
Healios KK
TSE:4593
Watchlist
Price: 196 JPY 0.51% Market Closed
Market Cap: 17.7B JPY
Have any thoughts about
Healios KK?
Write Note

Healios KK
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Healios KK
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Healios KK
TSE:4593
Cash Equivalents
ÂĄ4.5B
CAGR 3-Years
-35%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Cash Equivalents
ÂĄ16.3B
CAGR 3-Years
6%
CAGR 5-Years
21%
CAGR 10-Years
13%
PeptiDream Inc
TSE:4587
Cash Equivalents
ÂĄ50.4B
CAGR 3-Years
60%
CAGR 5-Years
43%
CAGR 10-Years
31%
Takara Bio Inc
TSE:4974
Cash Equivalents
ÂĄ38B
CAGR 3-Years
6%
CAGR 5-Years
14%
CAGR 10-Years
5%
Pharma Foods International Co Ltd
TSE:2929
Cash Equivalents
ÂĄ15.7B
CAGR 3-Years
17%
CAGR 5-Years
29%
CAGR 10-Years
26%
C
Cuorips Inc
TSE:4894
Cash Equivalents
ÂĄ5.6B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Healios KK
Glance View

Market Cap
17.7B JPY
Industry
Biotechnology

Healios KK engages in the research, development, and sale of cellular and regenerative medicine. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 116 full-time employees. The company went IPO on 2015-06-16. is a Japan-based company mainly engaged in research and development of pharmaceutical products. The firm has compound pharmaceutical products line and induced pluripotent stem cell (iPSC) regenerative medicine product line. The compound pharmaceutical product line contains HLM0021, HLM0022 and HLM0023. The products are ophthalmological surgery adjuvants, mainly contain brilliant blue G-250 (BBG250) which help capsule temporarily safely stained to protect the inner limiting membranes and lens during surgery of vitreous and cataract. The iPSC regenerative medicine product line contains HLCR011 and HLCR012. The products are in the preclinical testing and preparation for trial in Japan, which are candidate of regenerative medicine products. The products are iPS cell derived retinal pigment epithelium (RPE) cell suspension and sheet developed in Japan, United States and Europe.

Intrinsic Value
142.89 JPY
Overvaluation 27%
Intrinsic Value
Price

See Also

What is Healios KK's Cash Equivalents?
Cash Equivalents
4.5B JPY

Based on the financial report for Sep 30, 2024, Healios KK's Cash Equivalents amounts to 4.5B JPY.

What is Healios KK's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
-25%

Over the last year, the Cash Equivalents growth was -53%. The average annual Cash Equivalents growth rates for Healios KK have been -35% over the past three years , -25% over the past five years .

Back to Top